Rather, a discount in sales as a result of lower drug prices may reduce case study answer astronomical acquisition prices now being paid by case study solution large manufacturers to purchase ideas made by others. But case study solution biopharmaceutical ecosystem will proceed to thrive as long as those that in reality innovate are provided with case study answer substances to do so while folks that play other roles in bringing new drugs to market are fairly compensated for their contributions to those facets of case study solution development manner. As a recent report from case study answer National Academies of Medicine concluded, drugs that are not reasonably-priced are of little value and drugs that do not exist are of no value. case study answer problem of affordability should not solved if Congress continues to succumb to questionable assertions by lobbyists claiming that excessively high drug prices are vital to maintaining biopharmaceutical innovation. Passage of legislation to curb ridiculously high medicine prices and price increases will not only make drugs more available to patients but also will reduce executive expenses on drugs by greater than $345 billion dollars over 10 years, in line with case study answer Congressional Budget Office. That will enable case study answer government to make better investments in NIH and convey an excellent more robust biomedical innovation environment than now exists.